Harvard Bioscience, Inc., a global developer, manufacturer and marketer of a broad range of solutions to advance life science, announced that the Company has completed the previously announced acquisition of Data Sciences International, Inc. (DSI). The aggregate consideration payable by the Company in connection with the transaction is approximately $70 million (subject to adjustment for net working capital and other customary adjustments).

Simultaneous to the acquisition of DSI, the Company entered into a credit facility with Cerberus Business Finance, LLC, as administrative agent and collateral agent for the lenders. The Credit Facility is comprised of a $64 million term loan and a $25 million revolving line of credit, of which approximately $4.8 million was drawn at closing.